Irvine, CA — April 9, 2024 – Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (NYSE: KNW), an emerging developer of non-invasive medical diagnostic technology, announced it was selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California held on April 4-7, 2024.
The Company presented results titled, “Non-Invasive Blood Glucose Monitoring Using a Radiofrequency Sensor and a Machine Learning Model.” These results demonstrated that novel data preprocessing techniques, continued algorithm refinement and more high-resolution data improved the accuracy for Know Labs’ proprietary radiofrequency (RF) dielectric sensor in measuring blood glucose using a popular CGM as a comparative reference. These results were first published last year.
At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests. Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%. Compared to previous studies, in which most of the data collected was within the normoglycemic range and glucose values from a popular CGM were used as comparative reference, this study significantly increased the number of data points within the hyperglycemic range and therefore further validated the medical application of the Company’s proprietary sensor.
During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM), in large-scale, external clinical trials to determine real-world applicability, specifically the technology’s performance throughout continuous wear, on different locations on the body, and within more expansive glycemic ranges and diverse populations. To stay updated on the latest results, visit www.knowlabs.co/research-and-development.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.
Boustead Securities, LLC
Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com
Comments